Antitumor activities of combined treatment with a novel immunomodulator, (2S,3S,4R)-1-O-(α-D-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4- octadecanetriol (KRN7000), and radiotherapy in tumor-bearing mice

Oncology Research

Volumn 8, Issue 4, 1996, Pages 155-162

  Motoki, Kazuhiro ^a   Maeda, Kazuko ^a   Ueno, Hitomi ^a   Kobayashi, Eiichi ^a   Uchida, Takeshi ^a   Fukushima, Hideaki ^a   Koezuka, Yasuhiko ^a  

^a KIRIN BREWERY CO LTD   (Japan)

Author keywords

antitumor agent; immunomodulator; KRN7000; radiotherapy; galactosylceramide

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; FEMALE; FIBROSARCOMA; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; TUMOR ASSOCIATED LEUKOCYTE; WHOLE BODY RADIATION;

EID: 0029825087     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. 1. Fagundes, P.; Dische, S. Local tumor control and the subsequent incidence of distant metastatic disease. Int. J. Radiat. Oncol. Biol. Phys. 7:1645-1648; 1981.
2. 2. Gunar, K. Z.; Andrew, C. E.; Alberto, G. A.; Timothy, E. S.; Neil, E. S. The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy. Cancer 68: 2370-2377; 1991.
3. 3. Herman, D. S. Local control and patient survival. Int. J. Radiat. Oncol. Biol. Phys. 23:653-660; 1992.
4. 3H mice after treatment of implanted solid tumors with x-rays or surgery. Br. J. Cancer 30:342-348; 1974.
5. 5. Tubiana, M.; Arriagada, R.; Sarrazin, D. Human cancer natural history, radiation-induced immunodepression and postoperative radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 12:477-485; 1986.
6. 6. Fagundes, H.; Perez, C. A.; Grigsby, P. W.; Lockett, M. A. Distant metastases after irradiation alone in carcinoma of the uterine cervix. Int. J. Rad. Oncol. Biol. Phys. 24:197-204; 1992.
7. 7. Hochman, P. S.; Cudkowicz, G.; Dausset, J. Decline of natural killer cell activity in sublethally irradiated mice. J. Natl. Cancer Inst. 61:265-268; 1978.
8. 8. Ades, E. W.; Hinson, A; Butler, L. D. Natural cytolytic activity in mice with natural or induced cellular defects: I. Differential ability of in vitro interleukin-2 addition to augment natural cytolytic function. Cell. Immunol. 101:15-23; 1986.
9. 9. Yang, Z.; Tsuchiya, Y.; Arika, T.; Hosokawa, M. Effects of sizofiran on murine NK and LAK precursor cell activity suppressed by x-irradiation. Biotherapy 6:1663-1669; 1992.
10. 10. Okamura, K.; Suzuki M.; Chihara T; Fujiwara, A.; Fukuda T.; Goto, S.; Ichinohe, K.; Jimi, S.; Kasamatsu T.; Kawai, N.; Mizuguchi, K.; Mori S.; Nakano, H.; Noda, K.; Sekiba, K.; Suzuki, K.; Suzuki, T.; Takahashi, K.; Takeuchi, K.; Takeuchi, S.; Yajima, A; Ogawa, N. Clinical evaluation of schizophyllan combined with irradiation in patients with cervical cancer. Cancer 58: 865-872; 1986.
11. 11. Okawa, T.; Kita, M.; Arai, T.; Iida, K.; Dokiya, T.; Takegawa, Y.; Hitokawa, Y.; Yamazaki, K.; Hashimoto, S. Phase II randomized clinical trial of LC9018 concurrently used with radiation in the treatment of carcinoma of the uterine cervix. Cancer 64:1767-1776; 1989.
12. 12. Svennerholm, L.; Bruce A.; Mansson, J. E.; Rynmark, B. M.; Vanier, M. T. Sphingolipids of human skeletal muscle. Biochem. Biophys. Acta 280:626-636; 1972.
13. 13. Karlsson, K. A.; Samuelsson, B. E.; Steen, G. O. The sphingolipid composition of bovine kidney cortex, medulla and papilla. Biochem. Biophys. Acta 316: 317-335; 1973.
14. 14. Endo, M.; Nakagawa, M.; Hamamoto, Y.; Ishida, M. Pharmacologically active substances from southern Pacific marine invertebrates. Pure Appl. Chem. 1986: 387-394; 1986.
15. 15. Hirsh, S.; Kashma, Y. New glycosphingolipids from marine organisms. Tetrahedron 45:3897-3906; 1989.
16. 16. Morita, M.; Motoki, K.; Akimoto, K.; Natori, T.; Sakai, T.; Sawa, E.; Yamaji, K.; Kobayashi, E.; Fukushima, H.; Koezuka, Y. Structure-activity relationship of α-galactosylceramides against B16-bearing mice. J. Med. Chem. 38:2176-2187; 1995.
17. 3H/He mice. Oncology 40:115-119; 1983.
18. 18. Ogawa, Y.; Goodman, G. B.; Chaplin, D. J.; Grulkey, W.; Lam, G. K. Y. Combination therapy of pions and SPG (sonifilan, schizophyllan), a biological response modifier for mouse tumor systems. Int. J. Radiat. Oncol. Biol. Phys. 18:1415-1420; 1990.
19. 19. Kobayashi, E.; Motoki, K.; Uchida, T.; Fukushima, H.; Koezuka, Y. KRN7000, a novel immunomodulator and its antitumor activities. Oncol. Res. 7:529-534; 1996.
20. 20. Talmadge, J. E.; Herberman, R. B.; Chirigos, M. A.; Maluish, A. E.; Schneider, M. A.; Adams, J. S.; Philips, H.; Thurman, G. B.; Varesio, L.; Long, C.; Oldham, R. K.; Wiltrout, R. H. Hyporesponsiveness to augmentation of murine natural killer cell activity in different anatomical compartments by multiple injections of various immunomodulators including recombinant interferons and interleukin 2. J. Immunol. 135:2483-2491; 1985.
21. 21. Motoki, K.; Kobayashi, E.; Morita, M.; Uchida, T.; Akimoto, K.; Fukushima, H.; Koezuka, Y. Radioprotective effects of α-galactosylceramides. Bioorganic Med. Chem. Lett. 5:2413-2416; 1995.
22. 22.Doherty, P. C.; Knowles, B. B.; Wettstein, P. J. Immunological surveillance of tumors in the context of major histocompatibility restriction of T-cell function. Adv. Cancer Res. 42:1-65; 1984.
23. 23. Aebersold, P.; Hyatt, C.; Johnson, S.; Hines, K.; Korcak, L.; Sanders, M.; Lotze, M.; Topalian, S.; Yang, J.; Rosenberg, S. A. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes. J. Natl. Cancer Inst. 83:932-937; 1991.
24. 24. Cheever, M. A.; Greenberg, P. D.; Irie, C.; Thompson, J. A.; Urdal, D. L.; Mochizuki, D. Y.; Henney, C. S.; Gillis, S. Interleukin 2 administration in vivo induces the growth of cultured T cells in vivo. J. Immunol. 132: 2259-2265; 1984.
25. 25. Rosenberg, S. A.; Mule, J. J.; Spiess, P. J.; Reichert, C. M.; Schwartz, S. L. Regression of established pulmonary metastases and SC tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J. Exp. Med. 161:1169-1188; 1985.
26. 26. Lindahl, P.; Leary, P.; Gresser, I. Enhancement by interferon of the specific cytotoxity of sensitized lymphocytes. Proc. Natl. Acad. Sci. USA 69:721-725; 1972.
27. 27. Kataoka, T.; Oh-hashi, F.; Sakurai, Y.; Usauki, K.; Ida, N. Relative contribution of antiproliferative and host immunity-associated activity of mouse interferon in murine tumor therapy. Cancer Res. 44:5661-5665; 1984.
28. 28. Kataoka, T.; Matsuura, N.; Oh-hashi, F.; Suhara, Y. Treatment regimen and host T-cell dependent therapeutic effects of interferon in mouse solid tumors. Cancer Res. 45:3548-3553; 1985.
29. 29. Hirota, S.; Ogawa, Y.; Seguchi, H.; Histological analysis of lymphocyte subsets infiltrated into mouse tumor tissue exposed to local irradiation. Oncology 44:312-318; 1987.
30. 30. Ogawa, Y.; Maeda, T.; Seguchi, H.; Hamada, F.; Inomata, T.; Yoshida, S.; Kishimoto, S.; Saito, H. Infiltration of Leu-3a+3b-positive lymphocytes and expression of human leukocyte antigen DR on tumor tissue induced by radiation therapy. Oncology 45:18-20; 1988.
31. 31. Cheever, M. A.; Greenberg, P. D.; Fefer, A.; Gillis, S. Augmentation of the antitumor therapeutic efficacy of long-term cultured T-lymphocytes by in vivo administration of purified interleukin 2. J. Exp. Med. 155:968-980; 1982.
32. 32. Eberlein, T. J.; Rosenstein, M.; Rosenberg, S. A. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J. Exp. Med. 156:385-397; 1982.